Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Investor Day (November 2015)
131 slides from Precigen's investor day presentation, Nov 12, 2015
Slide 1: Investor Day | November 12, 2015
INVESTOR DAY | NOVEMBER 12, 2015 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements Special Note Regarding Forward-Looking Statements Some of the matters discussed in this presentation may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statem
Slide 3: Forward Looking Statements; Non-GAAP Financial Measures
Forward Looking Statements (xv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and (xvi) our expectations relating to AquaBounty, Trans Ova Genetics and Oxitec Limited. Intrexon does not undertake any obligation to update any forward-lookin
Slide 4: Company Introduction and Overview
Company Introduction and Overview Randal J. Kirk Chairman and Chief Executive Officer
Slide 5: Five Key Takeaways for Today
Five Key Takeaways for Today Expansive addressable markets Proprietary technologies and platforms Strong pipeline and substantial growth potential Capital efficient model for long-term value Strong management/ technical team © 2015 Intrexon Corp. All rights reserved.
Slide 6: Intrexon: Engineering Biology
Engineering Biology Intrexon: Engineering Biology © 2015 Intrexon Corp. All rights reserved.
Slide 7: Differentiated Synthetic Biology Platform
Differentiated Synthetic Biology Platform Thomas D. Reed, Ph.D. Founder and Chief Science Officer
Slide 8: Programming the Most Pervasive Code on the Planet
Programming the Most Pervasive Code on the Planet Software DNA Computers Living Things < Code Hardware > © 2015 Intrexon Corp. All rights reserved.
Slide 9: Biological Framework At Center of Operating System
Biological Framework At Center of Operating System © 2015 Intrexon Corp. All rights reserved.
Slide 10: A Platform To Program Code of Life…DNA
A Platform To Program Code of Life…DNA © 2015 Intrexon Corp. All rights reserved. Powerful programming & engineering platform for most pervasive code on the planet Utilize efficient biological processes to build better solutions faster and cheaper Expertise across increasing number of host systems 1
Slide 11: Design-Build-Test-Learn cycle
BUILD LEARN Each stage of model driven DBTL cycle integrates with bioinformatics platform TEST Exponential growth of cellular systems knowledge with each DBTL cycle Knowledge gained for different applications + different host systems as DNA code is universal Increasingly Valuable Database DESIGN © 2
Slide 12: Enabling Predictable Biological Discovery
Intrexon’s proprietary database maintains performance data on DNA parts, providing better designs and faster build times Data mining, modeling, and statistical analysis of the component library enable optimization and predictive biological experimentation Predictive ability removes time, cost and ri
Slide 13: Bioengineering Across Multiple Hosts Opens Large Markets
Bioengineering Across Multiple Hosts Opens Large Markets Intrexon’s Expression Host Expertise Health Gene and cellular therapies, API, biologics Food Agriculture, Aquaculture, Livestock Energy Fuels, Chemicals, Lubricants Environment Bioremediation, Sustainable Forestry Consumer Textiles, Personal C
Slide 14: Enabling Collaborators with Custom Biosolutions
Enabling Collaborators with Custom Biosolutions Intrexon Collaborator Domain Expertise End Market Strategy for Commercialization Biological Systems and Technology Leadership Alignment to design and commercialize better, faster, cheaper biosolutions © 2015 Intrexon Corp. All rights reserved.
Slide 15: Accelerating Concept to Candidate with Informatics
Accelerating Concept to Candidate with Informatics Mike Kubal Senior Manager, Informatics
Slide 16: Power of Intrexon Informatics
Power of Intrexon Informatics – Accelerating Concept to Candidate KNOWLEDGE FRAMEWORK Knowledge Management System Learn Algorithms & Models External Data Robust Internal Systems Fueling the Product Candidate Invention Engine Flexible and Scalable Informatics Ecosystem © 2015 Intrexon Corp. All right
Slide 17: Faster and Smarter: Predictive Capability
Predictive ability removes time, cost and risk inherent with standard experimentation 1260 Vectors: Best performer will be identified but at 4x cost + 2x time relative to 307 Vectors 500 Vectors: High probability of identifying hits, at mid-range time/cost 307 Vectors: Calculated risk in finding abs
Slide 18: BeyondBio: Our Centralized Database Platform
BeyondBio™: Our Centralized Database Platform BeyondBio™: A suite of tools for each stage of the Design-Build-Test-Learn™ workflow PathX Proprietary Learn Tool: Pathway Finding Pathway Generation Strain Design Target Pathway Non-target Pathway Non-target Pathway Expression Host © 2015 Intrexon Corp.
Slide 19: Connecting Learn and Design with PathX
Connecting Learn and Design with PathX PathX Advantages: Simulates actual metabolism of the host strain Significantly lowers cost of development No commercial or academic tool provides solution within context of a flux-balanced model © 2015 Intrexon Corp. All rights reserved.
Slide 20: Connecting Design with Commercial Targets for Partners
Connecting Design with Commercial Targets for Partners PathX allows Intrexon to quickly screen and prioritize vast numbers of potential targets for many industries from both a scientific and business perspective. Today PathX has identified potential biological routes for many target compounds with a
Slide 21: Beyond the Borders of Health with Better DNA
Beyond the Borders of Health with Better DNA® Samuel Broder, M.D. Senior Vice President, Health Sector
Slide 22: A Single Molecule at the Center of Biology
A Single Molecule at the Center of Biology © 2015 Intrexon Corp. All rights reserved.
Slide 23: Better DNA at the Center of Many Industries
Better DNA® at the Center of Many Industries © 2015 Intrexon Corp. All rights reserved.
Slide 24: Powering the Bioindustrial Revolution
Powering the Bioindustrial Revolution™ Hosts Better DNA®* Markets Human Plant Animal Bacteria Fungi Agriculture APIs Aquaculture Biologics CAR-T Cell Therapy Chemicals Consumer Products Fuels Gene Therapy Insect-Vector Control Livestock Genetic Programs Gene Delivery Systems Gene Expression Control
Slide 25: Creating a Sizeable Market Opportunity
Creating a Sizeable Market Opportunity Synthetic Biology Total Addressable Market Exceeds $1 Trillion © 2015 Intrexon Corp. All rights reserved.
Slide 26: Proprietary Approach for Gene Expression and Regulation
Proprietary Approach for Gene Expression and Regulation Peter Emtage, Ph.D. Vice President, Immunology
Slide 27: Evolution of Intrexon's Platform
Evolution of Intrexon’s Platform Up to 20 gene programs in a network; each containing up to 19 variable components Enables the architecture and construction of complex, integrated bio-functional systems Highly scalable; built on rapid design-build-test framework with intelligent software backbone Si
Slide 28: Our Extensive Expertise in DNA Delivery
Our Extensive Expertise in DNA Delivery Electroporation Chemical Transduction Direct Injection Autologous Allogeneic Adeno- virus (Ad) Adeno-associated Virus (AAV) Retrovirus / Lentivirus AttSite® Recombinases Sleeping Beauty attR attL 5’ Cap Poly AAA mRNA Stem Cells Viral Delivery Utilize many viru
Slide 29: Our Inducible Systems & Genome Engineering
Pseudo AttSite® recombinase mediated stable integration Intact transgene integration at low copy number into pseudo AttSites® in the genome 100% transgene integrity and 1–6 integrations per cell achieved Our Inducible Systems & Genome Engineering + recombinase Irreversible integration Chromosome att
Slide 30: RheoSwitch Platform Allows Controlled Approaches to Gene Therapies
RheoSwitch® Platform Allow for Controlled Approaches to New Gene Therapies S&I Ophthalmic Ocular Gene Therapy Chimeric Antigen Receptor (CAR-T) Brain Cancer Phase 1 Study CRADA with NCI Breast Cancer Phase 1b/2 Study © 2015 Intrexon Corp. All rights reserved.
Slide 31: RheoSwitch Regulated Expression of Bioactive RNA
RheoSwitch® Regulated Expression of Bioactive RNA Dose-dependent ligand-induced expression results in accumulation of mature, processed miRNA Inducibly-expressed miRNAs are functional, demonstrating knock-down of target genes New Solutions on the Horizon Time Course with Constant Enzyme Destabilized
Slide 32: Control & Delivery Empower Optimized Solutions
Control & Delivery Empower Optimized Solutions Improved Safety, Efficacy, and Manufacturing Autologous & Allogenic Solutions Cytokines scFv constructs Chimeric antigen receptors TCRs or Chimeric TCRs Chimeric co-stimulatory receptors Chemokines miRNA Gene editing techniques RheoSwitch® regulation Tr
Slide 33: Intrexon's Synthetic Immunology Efforts
Intrexon’s Synthetic Immunology Efforts Expanding Team of Scientists Viral & Non-viral gene delivery / Biological Effectors / Controlled Expression Knowledge Framework Driving Partner Solutions Through our Innovative DNA Engine © 2015 Intrexon Corp. All rights reserved.
Slide 34: Leveraging Viral DNA Delivery Tools for CAR-T
Leveraging Intrexon’s Viral DNA Delivery Tools for CAR-T Target CAR T cells T cells Expansion Transduce T cells Lentivirus Cytotoxicity IFNγ production CAR expression Saline Treated Target CAR Treated In vivo Tumor Cell Model © 2015 Intrexon Corp. All rights reserved.
Slide 35: Vast Opportunities in Gene and Cellular Therapy
Our broad platform engineers solutions for a number of diseases. Intrexon’s Vast Opportunities in Gene and Cellular Therapy © 2015 Intrexon Corp. All rights reserved.
Slide 36: Harnessing the power of the immune system to fight cancer
Harnessing the power of the immune system to fight cancer Laurence Cooper M.D., Ph.D. Chief Executive Officer, ZIOPHARM Oncology, Inc.
Slide 37: Synthetic Biology Leads to Powerful Engineering of Immune System
Synthetic Biology Leads to Powerful Engineering of Immune System Immune cells are capable of preventing and eliminating disease Yet the body’s own programming language governing an immune response is unable to eliminate tumor cells Genes can be engineered ex vivo to achieve in vivo anti-tumor effect
Slide 38: Intrexon & ZIOPHARM: Delivering Multimodal Gene Therapies
Intrexon & ZIOPHARM: Delivering Multimodal Gene Therapies Viral Therapy RTS ® Gene Switches Cell Therapy CAR-T, TCR and NK Cells Autologous and Allogeneic Viral & Non-viral Gene Integration © 2015 Intrexon Corp. All rights reserved.
Slide 39: Viral Gene Therapy: Ad-RTS-IL12 Ongoing Trials
Viral Gene Therapy: Ad-RTS-IL12 Ongoing Trials A single cycle of Ad-RTS-hIL-12 & escalating veledimex To establish: - Efficiency of veledimex crossing human BBB - Safety and tolerability - Determine MTD and immune response - Anti-tumor activity A single cycle of Ad-RTS-hIL-12 + veledimex Goal of mai
Slide 40: Portfolio of Cell Therapies to Address Oncology Landscape
Portfolio of Cell Therapies to Address Oncology Landscape CAR+ T cells Target cell surface tumor-associated antigens (TAAs) independent of HLA “Public” cell surface antigens TCR+ T cells Target intracellular TAAs dependent on HLA “Private” intra-cellular antigens NK cells Target tumor with loss of H
Slide 41: Building on the Progress of MDACC Trials for CAR+ T Therapy
Building on the Progress of MDACC Trials for CAR+ T Therapy Infusion of autologous T cells in patients with advanced non-Hodgkin lymphoma (NHL) Infusion of allogeneic T cells in patients with advanced CD19+ acute lymphoblastic leukemia or NHL CD19-directed CAR+ T therapies utilizing Sleeping Beauty
Slide 42: Portfolio of Next-generation Cell Therapies
Portfolio of Next-generation Cell Therapies CAR designs Cytokines Off-the-shelf Personalizing by targeting neo-antigens CAR+ T cells TCR+ T cells NK cells Cytokines Off-the-shelf Bioprocessing Manage the cost of immunotherapy and targeting solid tumors © 2015 Intrexon Corp. All rights reserved.
Slide 43: Engineering Off-the-Shelf CAR+ T-Cells
Engineering Off-the-Shelf CAR+ T-Cells Centralized manufacturing T cells can be prepared in advance of need T cells can be shipped to multiple points of care T cells can be infused on demand © 2015 Intrexon Corp. All rights reserved.
Slide 44: Strong Collaborations to Bring Therapeutics to Market
Strong Collaborations to Bring Therapeutics to Market © 2015 Intrexon Corp. All rights reserved. Intrexon : Oncology Intrexon: GvHD Merck KGaA via Intrexon NCI via Intrexon MD Anderson
Slide 45: Differentiated Platforms to Fight Cancer
Differentiated Platforms to Fight Cancer Intrexon Engine Ziopharm Implementation Harnessing synthetic biology to develop and implement a pipeline of therapeutics Update on clinical trials by year end 2015 New trials anticipated in 2016 © 2015 Intrexon Corp. All rights reserved.
Slide 46: Harnessing the Future
Harnessing the future 2015 2016+ Viral Gene Therapy Ad-RTS-IL-12 Glioma and Breast Expand Indications Combinations 2015 2016+ Adoptive Cell Therapy Hematological (ALL/NHL/CLL) Hematological (AML/MDS) CAR Design CAR & Cytokine Solid Tumors NK cells TCR Off-the-shelf © 2015 Intrexon Corp. All rights r
Slide 47: Therapeutic Approaches Beyond Cancer
Therapeutic Approaches Beyond Cancer Suma Krishnan Senior Vice President, Product Development & Head of Human Therapeutics Division
Slide 48: Collaborations For Diseases Beyond Cancer
Collaborations For Diseases Beyond Cancer Ocular Disease: Wet AMD Cartilage Repair: Off-The-Shelf Cells Rare Skin Disorders: RDEB Autoimmune: Allergies, GVHD Rare Diseases: Friedreich’s Ataxia Metabolic and GI disorders: Oral mucositis, PKU Cardiac Diseases: Heart Failure Infectious Diseases: C. dif
Slide 49: Targeting Significant Patient Population Beyond Cancer
Over 61 Million Patients Targeting Significant Patient Population Beyond Cancer © 2015 Intrexon Corp. All rights reserved.
Slide 50: Age-related Macular Degeneration (AMD)
Age-related Macular Degeneration (AMD) Estimated that 15 million people in the US affected by AMD* eye disease Wet AMD: - $6 Billion market *ASRS — http://www.asrs.org/patients/retinal-diseases/2/agerelated-macular-degeneration © 2015 Intrexon Corp. All rights reserved.
Slide 51: Next-gen RTS Controlled Gene Therapy Approach to Wet AMD
Next-gen RTS® Controlled Gene Therapy Approach to Wet AMD Intrexon and Sun Pharmaceuticals formed a joint venture to develop gene therapies for treatment of blinding ocular diseases Activator Ligand Protein of Interest Gene of Interest Next generation approach to Wet AMD utilizes RheoSwitch® platfor
Slide 52: On-Off-On Expression with RheoSwitch Platform
+AL +AL -AL +AL -AL +AL Eyes harvested Day 0, 14, 24, 34 On-Off-On Expression with RheoSwitch® Platform AAV-RTS-EPO proof of concept work: Demonstrated On-Off-On Effect via RTS® platform Sub-retinal Delivery of AAV-RTS-EPO Localizes EPO Expression to the Retina
Slide 53: Different Protein, Same Regulated Control with RTS
AL ON AL OFF AL OFF AL ON AL ON AL OFF AL ON AL OFF Different Protein, Same Regulated Control with RTS® AAV2-RTS-IFNa pre-clinical work: Tight control over gene programs in vivo AAV transduces target cells without systemic exposure AAV ocular administration doesn’t require immunosuppressants AAV int
Slide 54: Ligand Dosing Tunes Therapeutic Effect
AAV-RTS-EPO + AL (25mg/Kg) AAV-RTS-EPO + AL (5mg/Kg) AAV-RTS-EPO – AL PBS Naive RheoSwitch® Ligand Dosing Tunes Therapeutic Effect Protein Levels in the Eye in Pre-Clinical Model AAV-RTS-EPO pre-clinical work: Single Injection of AAV-RTS-EPO Controlled EPO Protein Expression via RTS® platform Dose D
Slide 55: Lead Therapeutic Candidate Showing Promising Results
Lead Therapeutic Candidate Showing Promising Results XON Therapeutic Control Isolectin B4 staining (Choroidal Neovascularization) Fluorescein Angiography (Vascular Leakage) Lead Candidate protects against laser-induced choroidal neovascularization and vascular leakage © 2015 Intrexon Corp. All right
Slide 56: CONFIDENTIAL © 2015 Intrexon Corp. All rights reserved.
CONFIDENTIAL © 2015 Intrexon Corp. All rights reserved.
Slide 57: Timeline for Development in Ophthalmic Program
Timeline for Development in Ophthalmic Program Sign JV with Sun Pharmaceuticals August 2013 File IND for Wet AMD in 2H 2016 Lead therapeutic candidate selected 2015 Research & development begins 2H 2013 Pre-clinical pharma/tox studies Q4 2015 Advance other clinical candidates © 2015 Intrexon Corp. A
Slide 58: Xogenex: Targeting Heart Failure with Novel Multigenic Approaches
Xogenex: Targeting Heart Failure with Novel Multigenic Approaches Amit Patel, M.D. Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah
Slide 59: Cardiac Disease – A Significant Unmet Medical Need
Cardiac Disease – A Significant Unmet Medical Need Source: http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm 25 Million Patients Worldwide 1 in 9 deaths List Heart Failure as Cause 825,000 New Cases a Year $32 Billion per Year Current Cost in U.S. Average Survival 40% 5 Years
Slide 60: Heart Failure Treatment Options
50,000-200,000 patients could benefit from cardiac replacement Only 2,200 donors in U.S. per year 3,500 heart transplants per year worldwide Immunosuppression issues Heart Failure Treatment Options Limited benefits Numerous side effects Do not stop progression of disease May reduce heart failure adm
Slide 61: Limited Success to Date with Heart Failure Biologics
Limited Success to Date with Heart Failure Biologics Stem Cells Costly approach Currently in clinical trials Mechanism of action unknown After 15 years no approved product or large scale positive trial Gene Therapy Currently in clinical trials Defined mechanism Current generation viral or single tar
Slide 62: Xogenex Solution: Multi-Genic Approach to Heart Failure
Xogenex Solution: Multi-Genic Approach to Heart Failure Heart failure is not a single gene defect disease but rather multimodal in its cause with multiple points in its pathway progression. Multigenic therapeutic delivered via single retrograde coronary sinus injection Angiogenesis Cell Homing Energ
Slide 63: First In Vitro Demonstration of Two Cardiac Effector Genes
Xogenex achieved first in vitro demonstration of protein expression from two cardiac effector genes driven by a single promoter in a single plasmid First In Vitro Demonstration of Two Cardiac Effector Genes Gene B Western blot (Cell Lysate) Gene A ELISA (Cell Supernatant) © 2015 Intrexon Corp. All r
Slide 64: Engineering Optimal Non-viral DNA Delivery
Engineering Optimal Non-viral DNA Delivery “XoX100” Construct Base Design Constitutive tissue specific promoter; two plasmid system No possibility of gene integration from recombinase mRNA pDNA expression specific to myocytes Inducible tissue specific promoter; two plasmid system Tissue specific and
Slide 65: Driving Persistent Expression
Driving Persistent Expression Data show average RLU of triplicate transfections. Error bars show Standard Error of the Mean. Persistent expression of Luciferase only in Att-Luc + SPBc2 transfection. Cells lacking AttSite® recombinase showed rapid return in signal to baseline. © 2015 Intrexon Corp. A
Slide 66: XoX: Pilot Small Pre-Human Luciferase Protein Expression
Day 56 XoX Construct – 250 µg XoX: Pilot Small Pre-Human Luciferase Protein Expression © 2015 Intrexon Corp. All rights reserved.
Slide 67: XoX: Pilot Large Pre-Human Data
XoX: Pilot Large Pre-Human Data Biodistribution of XoX Construct in large Pre-Human model Blue dye demonstrates both macro and micro distribution Reproducible © 2015 Intrexon Corp. All rights reserved.
Slide 68: Augment Standard of Care
Augment Standard of Care XOGENEX 20 million patients At Risk for Heart Failure Heart Failure © 2015 Intrexon Corp. All rights reserved.
Slide 69: Summary
Summary Novel multi-target approach for heart failure Multi-target approach 825,000 new cases annually Disease costs US approximately $32 Billion per Year Simple, reproducible, with possible re-dosing options Scientific Advisory Board experienced in retrograde biologics delivery in U.S. and globally
Slide 70: Third Generation Microbial Fermentation For Commercial Energy and Industrial Products
Third Generation Microbial Fermentation For Commercial Energy and Industrial Products Robert Walsh, Senior Vice President Head of Industrial Products Division
Slide 71: Evolution of Industrial Fermentation
Evolution of Industrial Fermentation Utilization of microorganisms like yeasts and bacteria to convert carbon and other molecules into valuable products via fermentation has continuously improved. Today the industrial fermentation industry exceeds $100 Billion. 1st Generation 2nd Generation 3rd Gene
Slide 72: Engineering a Novel GTL Technology Platform
Engineering a Novel GTL Technology Platform Intrexon is the first company to engineer the biology of a methanotroph to produce fuels and valuable industrial products from natural gas (NG). Natural Gas Fuels Chemicals Lubricants © 2015 Intrexon Corp. All rights reserved.
Slide 73: A Game Changer in Biofuel Economics
A Game Changer in Biofuel Economics Using natural gas as feedstock is game changer in producing biofuels via fermentation as it is the cheapest source of usable carbon today. Source: IEA-ETSAP and IRENA© Technology Brief P10 – January 2013 $ per Mbtu © 2015 Intrexon Corp. All rights reserved.
Slide 74: A More Attractive 'Drop-in Fuel'
A More Attractive ‘Drop-in Fuel’ The first target for Intrexon’s bioconversion platform is isobutanol, an attractive biofuel with competitive advantages versus other “drop in" gasoline replacement fuels or major additives 98% Energy Density of Gas Well Above Other Oxygenated Fuels No Corrosion to En
Slide 75: A More Profitable 'Drop-in Fuel'
A More Profitable ‘Drop-in Fuel’ * Based on Nov 11th natural gas prices, projected costs and yields ~44% gross margin versus typical fuel product margins of ~10%* 10 MMBTUs NG Feedstock ~$23/Barrel Non-Feedstock Opex ~$16/Barrel $39 Total Cost/ Barrel of Isobutanol NG feedstock, non-feedstock opex,
Slide 76: Gasoline Substitution Presents Significant Opportunity
Gasoline Substitution Presents Significant Opportunity Cleaner burning ‘drop in’ gasoline substitutes like isobutanol and ethanol represent an $80 Billion opportunity at 10% gasoline substitution globally. Total Worldwide Ethanol Production * U.S. Department of Energy http://www.afdc.energy.gov/fuel
Slide 77: Twice the Yield at One-Tenth the Input Cost
Twice the Yield at One-Tenth the Input Cost Intrexon chose to re-engineer methanotrophs’ DNA and genetic circuitry to produce valuable industrial products given its significantly superior yield potential in addition to lower feedstock cost Methanotroph Yield (w/w) Products Yeast Yield (w/w) 77 % Iso
Slide 78: Built a Genetic Toolbox that Didn't Exist
Built a Genetic Toolbox that Didn’t Exist Cell Systems Informatics Build in silico methanotroph model Define cellular pathways Control pathway expression DNA/RNA Engineering Build multiple constitutive and inducible promoters Construct shuttle vectors Advanced genome editing Protein Engineering Modi
Slide 79: Accelerating Improvement in Isobutanol Production
Accelerating Improvement in Isobutanol Production Relative Improvement 2500-fold increase in isobutanol production since early 2014 Exponential increase in productivity through applying Design-Build-Test-Learn to both Strain Engineering and Process Development Platform developed and de-risked © 2015
Slide 80: Path to Commercialization
Path to Commercialization Continue to drive improvements in yield Pilot facility operational in 2016 Anticipate site selection and construction of initial small scale commercial plant in 2016/2017 with partner Dominion Scalable platform leads to significant opportunity: - Small scale commercial faci
Slide 81: Platform Targets Beyond Isobutanol
Platform Targets Beyond Isobutanol 2015 2016 2017 2018 2019 Isobutanol Farnesene Butadiene Additional Candidates Engineered Production Commercial Sales Intrexon’s bioconversion platform utilizing the methanotroph unlocks vast potential to create valuable fuels and chemicals © 2015 Intrexon Corp. All
Slide 82: Driving Innovation in Food and Agriculture
Driving Innovation in Food and Agriculture Corey Huck Senior Vice President, Food Sector
Slide 83: Global Population Is the Growth Engine of Food Sector
Global Population Is the Growth Engine of Food Sector 9B 2050 7B 2015 © 2015 Intrexon Corp. All rights reserved.
Slide 84: Accelerating Food and Agricultural Innovation
Accelerating Food and Agricultural Innovation CONFIDENTIAL 75% More Food By 2050 Continued innovation required to meet population growth and market demands $797B Animal Protein Market by 2050* * FAO World Livestock 2011 © 2015 Intrexon Corp. All rights reserved.
Slide 85: Platform Opportunities
Platform Opportunities Crop Trait Development Animal Science Improving piglet weaning with ActoBiotics® Crop protection against insect and fungal pests through ActoBiotics® and Oxitec platforms Biologics to protect shrimp from disease Focus on specialty crops Non-browning quality in fruit and vegeta
Slide 86: Building Market Leadership Position
Building Market Leadership Position Game changing tech Drive consumer benefit Create new categories Drive participation across produce verticals Leading reproductive technologies Multiply elite genetics Expand to porcine Enable more protein Safe and sustainable Improve productivity Accelerate curren
Slide 87: Driving unparalleled productivity advancements for food production
Driving unparalleled productivity advancements for efficient, high-quality food production David Faber, DVM President CEO of Trans Ova
Slide 88: Livestock Industry Plays Key Role in Global Protein Supply
Livestock Industry Plays Key Role in Global Protein Supply Today: Dairy production value exceeds $180 billion Beef production value exceeds $172 billion By 2050: Over 9 billion people Will require twice as much dairy Will require twice as much meat © 2015 Intrexon Corp. All rights reserved.
Slide 89: Trans Ova #1 Driver of Bovine Genetics in North America
Trans Ova #1 Driver of Bovine Genetics in North America Trans Ova at forefront of expanding genetic gains through elite cows Preeminent market share in IVF and Embryo Transfer Largest supplier/producer of bovine embryos in the U.S. Produces elite dairy heifers and top breeding bulls © 2015 Intrexon
Slide 90: Service Platform Driving Reproductive Improvement
Service Platform Driving Reproductive Improvement 1970s: Elite cows 0-2 offspring annually Today: 40-60 offspring from Elite cows annually Trans Ova’s industry-leading reproductive technologies driving significant improvements in productivity of elite cows within the dairy industry Artificial Insemi
Slide 91: Our Platform Today Enables Superior Genetic Gains
In the April 2014 Top Young Genomic Bull List, 87% of the top 100 bulls were produced by Trans Ova and the clients it serves Our Platform Today Enables Superior Genetic Gains Genetic Gain Daughters with more milk, health and longevity Accuracy x Genetic Variation x Selection Intensity Generation Int
Slide 92: Growing Impact of Genetics in U.S. Dairy Industry
Growing Impact of Genetics in U.S. Dairy Industry *Source: USDA - http://www.ers.usda.gov/media/1013586/oce131e.pdf; **Genetic Merit corresponds to increases of 4, 9, and 16 gallons of annual milk production per cow without a decrease in cow health, fertility, or survival; *** Source: Dairy Manageme
Slide 93: Intrexon's Technologies Dramatically Further Genomic Impact
Intrexon’s Technologies Dramatically Further Genomic Impact Current breeding practices emphasize male genetics, overlooking an important source of improvement through the genetics of the cow Artificial insemination is a driver of genetic merit in the bovine industry Intrexon technologies will enable
Slide 94: Portfolio Balance
Portfolio Balance Existing New Core Competencies Markets Existing New Enhanced genetic gain via genomic screening, IVF and cloning improvements, EPC and velogenesis Bovine and porcine nucleus herd development F1 embryos for dairy replacement females Enhanced precision breeding Growing the existing A
Slide 95: Positioning Company to Enable Unparalleled Food Productivity
Positioning Company to Enable Unparalleled Food Productivity Expansion of product line to include embryos, with power of both female and male genetics, opens door to unparalleled productivity advancements for efficient, high-quality food production globally Significant Opportunities Trans Ova’s Curr
Slide 96: Non-Browning Arctic Apples: A Game-Changer for Fresh Produce
NON-BROWNING ARCTIC® APPLES A Game-Changer for Fresh Produce Neal Carter President & Founder, Okanagan Specialty Fruits
Slide 97: Leading "Biotech 2.0" Product
Leading “Biotech 2.0” Product Arctic® apples will not brown when bitten, sliced or bruised Have only silenced genes, no new proteins added to fruit Among first GE crops with a direct consumer benefit First GE apple to receive regulatory approvals in US and Canada © 2015 Intrexon Corp. All rights res
Slide 98: An Innovative Biotech Approach
An Innovative Biotech Approach Using RNAi technology, we reduced the expression of PPO, the enzyme responsible for oxidative browning Almost any apple variety and other produce can be enhanced with the non-browning trait Conventional Apple PPO Enzyme Reduced Arctic Apples © 2015 Intrexon Corp. All r
Slide 99: Approved in United States and Canada
Approved in United States and Canada Regulatory Approval and Consumer Acceptance Our consumer surveys have found favorable reaction to non-browning apples Information of how GE is used to silence browning genes increased consumer acceptance 51% 59% Consumers responding “likely” or “very likely” to b
Slide 100: Non-Browning Benefits Across Supply Chain
Non-Browning Benefits Across Supply Chain 55% of consumers consider browning to be a significant issue1 Per capita U.S. apple consumption declined 20% between 1991 and 20112; this trend continues At least 40% of apples produced are never consumed; among most wasted foods3 1OSF (2013) 2USDA ERS (2012
Slide 101: Arctic Advantage Drivers to Increase Market Share
Arctic Advantage™ Drivers to Increase Market Share Apples are #1 fruit for ages 2–19 in U.S. Snacks = ~50% of eating occasions Avoid “off-taste” from anti-browning treatments Reduce processing costs by up to 40% © 2015 Intrexon Corp. All rights reserved.
Slide 102: Technology Enables Apple Participation in Fast-Growing Fresh Cut Market
Technology Enables Apple Participation in Fast-Growing Fresh Cut Market “Convenience — the #1 reason for purchase” Retail freshcut dollar & volume sales are increasing and food service demand for freshcut is increasing even faster Freshcut produce makes up 16% of total retail produce sales Less than
Slide 103: Arctic Apples – Creating A New Food Category
Arctic® Apples – Creating A New Food Category Arctic® Leather Arctic® Leather Arctic® Apple Slices Arctic® Smoothie
Slide 104: Arctic Platform Beyond Apples
Arctic® Platform Beyond Apples Arctic® platform will create consumption and profit triggers in untapped markets The non-browning trait will allow for new innovative fresh apple products Consumer acceptance helps open the door for the use of biotech in specialty crops Intrexon is expanding the Arctic
Slide 105: Arctic Platform Beyond Apples
Arctic® Platform Beyond Apples © 2015 Intrexon Corp. All rights reserved. Q1 2015 Cleared regulatory obligations: USDA, FDA, CFIA & HC Q2 2015 First commercial orchards of Arctic ® apples planted Apply for regulatory approval in other countries 2015-2018 Development of non-browning pears, cherries a
Slide 106: Environmentally Friendly Insect Control Solutions
Environmentally Friendly Insect Control Solutions for Major Global Disease and Agricultural Challenges Hadyn Parry Chief Executive Officer, Oxitec
Slide 107: The Challenge: Mosquito Borne Diseases
The Challenge: Mosquito Borne Diseases “Today, dengue ranks as the most important mosquito-borne viral disease in the world. Everywhere the human and economic costs are staggering” Dr Margaret Chan, 2012 Director General, WHO Dengue fever © 2015 Intrexon Corp. All rights reserved.
Slide 108: Our Enemy
Our Enemy © 2015 Intrexon Corp. All rights reserved.
Slide 109: Aedes Aegypti: Invasive Species
Aedes Aegypti: Invasive Species in over 100 Countries Today Uncertain Likely Present Source: http://www.healthmap.org/dengue/en/ © 2015 Intrexon Corp. All rights reserved.
Slide 110: Current 'Modern' Practice
Current ‘Modern’ Practice © 2015 Intrexon Corp. All rights reserved.
Slide 111: Our Solution
Our Solution © 2015 Intrexon Corp. All rights reserved.
Slide 112: Self Limiting Gene
Self Limiting Gene Oxitec’s OX513A – two inserted traits Fluorescent Marker Gene Oxitec male mosquitoes are produced for release and mate with pest females Offspring die before they can reproduce and transmit disease Inject genes into insect egg © 2015 Intrexon Corp. All rights reserved.
Slide 113: Production and Release
Production and Release More than 100 million Oxitec mosquitoes released worldwide © 2015 Intrexon Corp. All rights reserved.
Slide 114: OX513A Results in Mandacaru, Brazil
OX513A Results in Mandacaru, Brazil Objectives: Effective suppression Reduction in eggs — 93% Reduction in adults — 96% Sustained control Utilize seasonality Releases ovitrap index Treated area Untreated area Wet Season © 2015 Intrexon Corp. All rights reserved.
Slide 115: Oxitec Field Results Show Dramatic Impact
Oxitec Field Results Show Dramatic Impact Cayman Islands Pedra Branca Mandacaru Itaberaba Panama 96% 92% 99% 94% 93% Aedes aegypti field trials show greater than 92% mosquito suppression Cayman Islands: Mosquito Research Control Unit Brazil: University of Sao Paulo and Moscamed Panama: The Gorgas In
Slide 116: Large Opportunities in Agriculture
Large Opportunities in Agriculture 40% Global Food Production Lost to Insect Related Crop Damage $11 Billion Spent Annually on Conventional Insecticides © 2015 Intrexon Corp. All rights reserved.
Slide 117: Brazil: A Case Study
Brazil: A Case Study Early 1970s No Aedes aegypti No dengue Brazilian press describe our product as Aedes aegypti do bem: ‘the good mosquito’ 96% of local Piracicaba residents support the Oxitec program Recent years 0.5m — 1.5m cases of dengue per year Over $1 billion spent on the dengue vector cont
Slide 118: Synergistic Solutions with Value in Large, Growing Markets
Synergistic Solutions with Value in Large, Growing Markets Adjacent Market Examples Losses due to insects Cattle flies $3.6B Pig house flies$0.3B Culex $1.0B Agriculture Insecticide market $11B Losses due to insects DBM$ 4B Corn earworm$14B Soya stinkbugs$ 7B 1.http://www.idcostcalc.org/contents/den
Slide 119: Benefits to the Ecosystem and Beyond
Benefits to the Ecosystem and Beyond Oxitec’s biological solution is exquisitely directed toward single insect pest species High efficacy Toxin-free Male-only releases Avoids off-target effects towards beneficial insects like bees Heritable visible marker Self-limiting in environment Targets some of
Slide 120: Multiple Paths to Shareholder Value
Multiple Paths to Shareholder Value Joel Liffmann Senior Vice President, Finance
Slide 121: Third Quarter and Nine Month Results
Third Quarter and Nine Month Results Fiscal Year 2015 Financials Third Quarter YTD Revenues $53.4 M $132.1 M Net loss attributable to Intrexon $38.2 M $51.8 M Basic EPS $(0.34) $(0.47) Adjusted EBITDA $3.8 M* $43.6 M* Basic adjusted EBITDA per share $0.03* $0.40* Total Cash and Investments (excludin
Slide 122: Organized To Reach Broad Market Potential
Organized To Reach Broad Market Potential Operating Subsidiaries and Channel Collaborators Operating Units Drive Technology and Platforms Health | Consumer | Environment | Energy | Food Synthetic Immunology Division Agricultural Biotech Division Human Therapeutics Division Animal Sciences Division I
Slide 123: Flexible and Financially Disciplined Business Model
Flexible and Financially Disciplined Business Model Exclusive Channel Collaborations (ECCs) Joint Ventures (JVs) Start Ups M&A Opportunities © 2015 Intrexon Corp. All rights reserved.
Slide 124: ECCs allow Intrexon to Scale and Leverage R&D
ECCs allow Intrexon to Scale and Leverage R & D ECC Model initiated in 2011 enabling broad application of our technology across many diverse end markets Today we have 26 active ECCs and three research collaborations that could become commercial agreements © 2015 Intrexon Corp. All rights reserved. E
Slide 125: ECC Model at Work Today
ECC Model at Work Today Cumulative Technology Access Fees and Milestone Payments = $211.2 million Cumulative Cost Recovery Revenues = $102.1 million © 2015 Intrexon Corp. All rights reserved.
Slide 126: ECC Model at Work Tomorrow
ECC Model at Work Tomorrow Growing portfolio of backend economics with royalties ranging from mid-single digits of net sales to 50% of net operating profits © 2015 Intrexon Corp. All rights reserved.
Slide 127: JVs Provide Valuable Future Growth Opportunities
JVs Provide Valuable Future Growth Opportunities Joint Venture Partner / Intrexon Shared Economics Shared Costs Defined Field JV Model initiated in 2014 3 joint ventures today in which we share of operating costs and future profits with our partners © 2015 Intrexon Corp. All rights reserved.
Slide 128: Successful M&A Strategy: Proactive, Deliberate and Focused
Successful M&A Strategy: Proactive, Deliberate and Focused Target sectors that are positioned to gain from the disruptive potential of bioengineering Identify companies: With attractive stand alone financial and commercial profiles That add complimentary technologies to our resources; and/or That ca
Slide 129: Start Up Investments: Visibility to Next-Gen Opportunities
Start Up Investments: Visibility to Next-Gen Opportunities First ECC: Thrive Agrobiotics, Inc., Sept 2015 Why: Thrive will access Intrexon’s ActoBiotics® platform to develop animal feed supplements Market need: Pork is the most consumed meat in the world today, playing an important role in the suppl
Slide 130: Summary
Summary Intrexon is well positioned to effectively capitalize on the opportunities within Synthetic Biology Capital efficient ECC model lowers risk and delivers shareholder value Strong financial position to execute strategic plan Significant potential for growth Disciplined business model and appro
Slide 131: Investor Day | November 12, 2015
INVESTOR DAY | NOVEMBER 12, 2015